Rx Name [LAMIVUDINE, 08180820]
|
|
3TC 10MG/ML SOLUTION (GSK/COL) LAMIVUDINE
|
|
|
|
|
|
08180820
|
|
|
NRTI
|
|
|
A combination of oral lamivudine and oral zidovudine has p roduced significant and sustained increases in CD4+ counts and decreases in viral load in HIV-infected patients. Lamivudine is indicated for the treatment of chronic hepatitis B associated with e
|
|
|
Diarrhoea, headache, fatigue, insomnia, arthralgias, myalgias, neuropathy, nasal signs and symptoms, elevated liver enzymes, skin rash, fever or chills, ear, nose and throat infections. Concurrent use with co-trimoxazole may result in increased adverse effects from lamivudine. Dose adjustment of lamivudine may be necessary .
|
|
|
Adult: 150mg orally twice daily , or 300mg once daily . Pediatric 3 months - 16 years: 4mg/kg twice daily (up to a maximum dose of
150mg twice a day ). Chronic hep atitis B: 100mg orally daily for adults and 3mg/kg once daily (maximum daily dose = |
|
|
|
|
|
The animal and human data suggest that lamivudine is a low risk to the developing fetus for structural malformations. Theoretically, exposure to agents in this class at the time of implantation could result in impaired fertility as a result of embryonic c
|
|
|
Lamivudine is distributed into milk in humans. It is not known whether the drug affects human milk production or affects the breast-fed infant. The breast-fed infant can experience potential adverse effects of the drug.
|
|
|
|